Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

371 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
High serum angiopoietin-2 level predicts non-regression of liver stiffness measurement-based liver fibrosis stage after direct-acting antiviral therapy for hepatitis C.
Kawagishi N, Suda G, Kimura M, Maehara O, Shimazaki T, Yamada R, Kitagataya T, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Umemura M, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Kudo Y, Nishida M, Sakamoto N. Kawagishi N, et al. Among authors: shimazaki t. Hepatol Res. 2020 Jun;50(6):671-681. doi: 10.1111/hepr.13490. Epub 2020 Feb 18. Hepatol Res. 2020. PMID: 32020702 Free article.
Assessing the risk of hepatocellular carcinoma by combining liver stiffness and the controlled attenuation parameter.
Izumi T, Sho T, Morikawa K, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Kawagishi N, Umemura M, Shimazaki T, Kimura M, Nakai M, Suda G, Natsuizaka M, Ogawa K, Kudo Y, Nishida M, Ono K, Baba M, Furuya K, Sakamoto N. Izumi T, et al. Among authors: shimazaki t. Hepatol Res. 2019 Oct;49(10):1207-1217. doi: 10.1111/hepr.13391. Epub 2019 Jul 10. Hepatol Res. 2019. PMID: 31219667
Entecavir treatment of hepatitis B virus-infected patients with severe renal impairment and those on hemodialysis.
Suzuki K, Suda G, Yamamoto Y, Furuya K, Baba M, Kimura M, Maehara O, Shimazaki T, Yamamoto K, Shigesawa T, Nakamura A, Ohara M, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Sakamoto N; NORTE Study Group. Suzuki K, et al. Among authors: shimazaki t. Hepatol Res. 2019 Nov;49(11):1294-1304. doi: 10.1111/hepr.13399. Epub 2019 Jul 25. Hepatol Res. 2019. PMID: 31260579
Effects of resistance-associated variants in genotype 2 hepatitis C virus on viral replication and susceptibility to antihepatitis C virus drugs.
Suda G, Kimura M, Shigesawa T, Suzuki K, Nakamura A, Ohara M, Kawagishi N, Nakai M, Sho T, Maehara O, Shimazaki T, Morikawa K, Natsuizaka M, Ogawa K, Sakamoto N. Suda G, et al. Among authors: shimazaki t. Hepatol Res. 2019 Nov;49(11):1275-1285. doi: 10.1111/hepr.13401. Epub 2019 Jul 23. Hepatol Res. 2019. PMID: 31261439
Analysis of the optimal psoas muscle mass index cut-off values, as measured by computed tomography, for the diagnosis of loss of skeletal muscle mass in Japanese people.
Ohara M, Suda G, Kimura M, Maehara O, Shimazaki T, Shigesawa T, Suzuki K, Nakamura A, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ogawa K, Kobayashi T, Uebayashi M, Takagi R, Yokota I, Shimamura T, Sakamoto N. Ohara M, et al. Among authors: shimazaki t. Hepatol Res. 2020 Jun;50(6):715-725. doi: 10.1111/hepr.13499. Epub 2020 Apr 7. Hepatol Res. 2020. PMID: 32202371
The potential of soluble CD14 in discriminating nonalcoholic steatohepatitis from nonalcoholic fatty liver disease.
Nakamura A, Yamamoto K, Takeda R, Yamada R, Kubo A, Morikawa K, Ando S, Shimazaki T, Izumi T, Umemura M, Kitagataya T, Shigesawa T, Suzuki K, Kimura M, Nakai M, Sho T, Suda G, Natsuizaka M, Ogawa K, Ohnishi S, Sugiyama T, Takeda H, Sakamoto N. Nakamura A, et al. Among authors: shimazaki t. Hepatol Res. 2022 Jun;52(6):508-521. doi: 10.1111/hepr.13757. Epub 2022 Feb 22. Hepatol Res. 2022. PMID: 35129841
Effects of nucleos(t)ide analogs on hepatitis B surface antigen reduction with interferon-lambda 3 induction in chronic hepatitis B patients.
Umemura M, Ogawa K, Morikawa K, Kubo A, Tokuchi Y, Yamada R, Kitagataya T, Shigesawa T, Shimazaki T, Kimura M, Suzuki K, Nakamura A, Ohara M, Kawagishi N, Izumi T, Nakai M, Sho T, Suda G, Natsuizaka M, Ono K, Murata K, Sugiyama M, Mizokami M, Sakamoto N. Umemura M, et al. Among authors: shimazaki t. Hepatol Res. 2022 Jul;52(7):586-596. doi: 10.1111/hepr.13768. Epub 2022 Apr 12. Hepatol Res. 2022. PMID: 35352445
Anti-adipogenic and antiviral effects of l-carnitine on hepatitis C virus infection.
Tsukuda Y, Suda G, Tsunematsu S, Ito J, Sato F, Terashita K, Nakai M, Sho T, Maehara O, Shimazaki T, Kimura M, Morikawa K, Natsuizaka M, Ogawa K, Ohnishi S, Chuma M, Sakamoto N. Tsukuda Y, et al. Among authors: shimazaki t. J Med Virol. 2017 May;89(5):857-866. doi: 10.1002/jmv.24692. Epub 2016 Oct 3. J Med Virol. 2017. PMID: 27664407
L-Carnitine Suppresses Loss of Skeletal Muscle Mass in Patients With Liver Cirrhosis.
Ohara M, Ogawa K, Suda G, Kimura M, Maehara O, Shimazaki T, Suzuki K, Nakamura A, Umemura M, Izumi T, Kawagishi N, Nakai M, Sho T, Natsuizaka M, Morikawa K, Ohnishi S, Sakamoto N. Ohara M, et al. Among authors: shimazaki t. Hepatol Commun. 2018 Aug 6;2(8):906-918. doi: 10.1002/hep4.1207. eCollection 2018 Aug. Hepatol Commun. 2018. PMID: 30094402 Free PMC article.
371 results